A mini-review of c-Met as a potential therapeutic target in melanoma.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

• Publication date

  2017-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.biopha.2017.01.045PMID 28107696
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer treatment and survivorship statistics, 2016

  2016cited by this paper
• The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma.

  2016cited by this paper
• Cancer statistics, 2016

  2016cited by this paper
• Discovery of novel pyrrolo[2,3-b]pyridine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.

  2016cited by this paper
• Implementation of a hospital-integrated general practice--a successful way to reduce the burden of inappropriate emergency-department use.

  2016cited by this paper
• Final results: A dose escalation phase I study of ARQ 197, a selective c-Met inhibitor, in patients with metastatic solid tumors.

  2016cited by this paper
• Epigenetic Silencing of SPINT2 promotes Cancer Cell Motility via HGF-MET Pathway Activation in Melanoma

  2015cited by this paper
• Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion

  2015cited by this paper
• A melanin‐independent interaction between Mc1r and Met signaling pathways is required for HGF‐dependent melanoma

  2015cited by this paper
• Targeting c-Met in melanoma

  2014cited by this paper
• Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors

  2014cited by this paper
• The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.

  2014cited by this paper
• Incidence of new primary melanomas after diagnosis of stage III and IV melanoma.

  2014cited by this paper
• Neural basis of the perception and estimation of time.

  2013cited by this paper
• Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model

  2013cited by this paper
• Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.

  2013cited by this paper
• Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights

  2012cited by this paper
• Epithelial-mesenchymal transitions: insights from development

  2012cited by this paper
• Activity of cabozantinib (XL184) in metastatic melanoma: Results from a phase II randomized discontinuation trial (RDT).

  2012cited by this paper
• Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.

  2011cited by this paper
• Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.

  2010cited by this paper
• Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.

  2010cited by this paper
• Hepatocyte growth factor activator (HGFA): pathophysiological functions in vivo

  2010cited by this paper
• Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cited by this paper
• MET signalling: principles and functions in development, organ regeneration and cancer

  2010cited by this paper
• Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma

  2010cited by this paper
• Phase I dose escalation trial (ARQ 197-111) evaluating combination of selective c-Met inhibitor ARQ 197 and erlotinib.

  2009cited by this paper
• Final results of a pharmacokinetic (PK) and pharmacodynamic (PD) phase I trial of ARQ 197 incorporating dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) studies investigating the antiangiogenic activity of selective c-Met inhibition.

  2009cited by this paper
• Oncogenic Braf induces melanocyte senescence and melanoma in mice.

  2009cited by this paper
• Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.

  2009cited by this paper
• Preliminary results from a phase II study of ARQ 197 in patients with microphthalmia transcription factor family (MiT)-associated tumors.

  2009cited by this paper
• Rilotumumab, a mAb against human hepatocyte growth factor for the treatment of cancer.

  2009cited by this paper
• Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066.

  2009cited by this paper
• Phase I study of daily administration of MGCD265 to patients with advanced malignancies (Study 265-101).

  2009cited by this paper
• Crosstalk in Met receptor oncogenesis.

  2009cited by this paper
• A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse.

  2009cited by this paper
• Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.

  2009cited by this paper
• Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer

  2009cited by this paper
• Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.

  2008cited by this paper
• A Novel Recombinant Soluble Splice Variant of Met Is a Potent Antagonist of the Hepatocyte Growth Factor/Scatter Factor-Met Pathway

  2008cited by this paper
• The biological role of HGF-MET axis in tumor growth and development of metastasis.

  2008cited by this paper
• BRAFE600 in benign and malignant human tumours

  2008cited by this paper
• 552 POSTER Targeting MET with XL184 to reverse EGFR tyrosine kinase inhibitor (TKI) resistance in NSCLC: impact of preclinical studies on clinical trial design

  2008cited by this paper
• JNJ-38877605: a selective Met kinase inhibitor inducing regression of Met-driven tumor models.

  2008cited by this paper
• Discovery and characterization of INCB028060, a novel, potent and selective Met RTK inhibitor for cancer treatment

  2008cited by this paper
• Showering c-MET-dependent cancers with drugs.

  2008cited by this paper
• AMG 102, A Fully Human Anti-Hepatocyte Growth Factor/Scatter Factor Neutralizing Antibody, Enhances the Efficacy of Temozolomide or Docetaxel in U-87 MG Cells and Xenografts

  2007cited by this paper
• An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.

  2007cited by this paper
• A Phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics of XL880, a VEGFR and MET kinase inhibitor, administered daily to patients (pts) with advanced malignancies

  2007cited by this paper
• Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors

  2007cited by this paper
• RaLP, a new member of the Src homology and collagen family, regulates cell migration and tumor growth of metastatic melanomas.

  2007cited by this paper
• A phase I study of a novel spectrum selective kinase inhibitor (SSKI), XL880, administered orally in patients (pts) with advanced solid tumors (STs).

  2006cited by this paper
• Somatic activation of KIT in distinct subtypes of melanoma.

  2006cited by this paper
• Pathology and genetics of skin tumours

  2006cited by this paper
• Therapeutic targeting of receptor tyrosine kinases in lung cancer

  2005cited by this paper
• Distinct sets of genetic alterations in melanoma.

  2005cited by this paper
• Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.

  2005cited by this paper
• Cutaneous melanoma.

  2005cited by this paper
• Etiologic Pathogenesis of Melanoma

  2004cited by this paper
• p16INK4a and p14ARF tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma.

  2004cited by this paper
• The p16INK4a-RB pathway: molecular link between cellular senescence and tumor suppression.

  2004cited by this paper
• Breast carcinoma: a collective disorder

  2004cited by this paper
• Human melanocyte senescence and melanoma susceptibility genes

  2003cited by this paper
• Is there a role for genetic testing in patients with melanoma?

  2003cited by this paper
• Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor

  2003cited by this paper
• A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.

  2003cited by this paper
• Expression of c-met Tyrosine Kinase Receptor Is Biologically and Prognostically Relevant for Primary Cutaneous Malignant Melanomas

  2003cited by this paper
• GM-CSF-secreting melanoma vaccines

  2003cited by this paper
• Scatter-factor and semaphorin receptors: cell signalling for invasive growth

  2002cited by this paper
• Cellular and Molecular Biology of Human Melanoma

  2002cited by this paper
• Geographical variation in the penetrance of CDKN2A mutations for melanoma.

  2002cited by this paper
• Roles of activated Src and Stat3 signaling in melanoma tumor cell growth

  2002cited by this paper
• Cbl: many adaptations to regulate protein tyrosine kinases

  2001cited by this paper
• Potent Blockade of Hepatocyte Growth Factor-stimulated Cell Motility, Matrix Invasion and Branching Morphogenesis by Antagonists of Grb2 Src Homology 2 Domain Interactions*

  2001cited by this paper
• Malignant melanoma.

  2001cited by this paper
• Malignant melanoma: An update

  2001cited by this paper
• Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin.

  2000cited by this paper
• Nk4, a new HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells

  2000cited by this paper
• Bone Morphogenetic Protein-15

  2000cited by this paper
• Tumorigenesis mediated by MET mutant M1268T is inhibited by dominant-negative Src

  2000cited by this paper
• The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.

  2000cited by this paper
• Involvement of an SHP-2-Rho small G protein pathway in hepatocyte growth factor/scatter factor-induced cell scattering.

  2000cited by this paper
• The von Hippel-Lindau Tumor Suppressor Gene Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Invasion and Branching Morphogenesis in Renal Carcinoma Cells

  1999cited by this paper
• Ligand-induced Ubiquitination of the Epidermal Growth Factor Receptor Involves the Interaction of the c-Cbl RING Finger and UbcH7*

  1999cited by this paper
• cbl-3: a new mammalian cbl family protein

  1999cited by this paper
• The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase.

  1999cited by this paper
• Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype.

  1999cited by this paper
• A Peptide Representing the Carboxyl-terminal Tail of the Met Receptor Inhibits Kinase Activity and Invasive Growth*

  1999cited by this paper
• Induction of epithelial tubules by growth factor HGF depends on the STAT pathway

  1998cited by this paper
• bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice

  1998cited by this paper
• c-Src Kinase Activity Is Required for Hepatocyte Growth Factor-induced Motility and Anchorage-independent Growth of Mammary Carcinoma Cells*

  1998cited by this paper
• The molecular basis of nonmelanoma skin cancer: new understanding.

  1997cited by this paper
• Hepatocyte Growth Factor Activator Inhibitor, a Novel Kunitz-type Serine Protease Inhibitor*

  1997cited by this paper
• Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis

  1996cited by this paper
• Branching Tubulogenesis but Not Scatter of Madin-Darby Canine Kidney Cells Requires a Functional Grb2 Binding Site in the Met Receptor Tyrosine Kinase*

  1996cited by this paper
• Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis.

  1995cited by this paper
• The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein.

  1995cited by this paper
• Biomarkers associated with prostate cancer progression.

  1994cited by this paper
• A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family.

  1994cited by this paper
• Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression.

  1993cited by this paper

• MET amplification correlates with poor prognosis and immunotherapy response as a subtype of melanoma: a multicenter retrospective study

  2024cites this paper
• Computational Simulation Study of Potential Inhibition of c‐Met Kinase Receptor by Phenoxy pyridine Derivatives: Based on QSAR, Molecular Docking, Molecular Dynamics

  2024cites this paper
• Design, synthesis and pharmacological evaluation of novel thiazole derivatives as c-Met kinase inhibitors and anticancer agents

  2024cites this paper
• Advances in the selective c-MET kinase inhibitors: Application of fused [5,6]-Bicyclic nitrogen-containing cores for anticancer drug design.

  2024cites this paper
• Dissecting the effects of METTL3 on alternative splicing in prostate cancer

  2023cites this paper
• Expression and Prognostic Evaluation of the Receptor Tyrosine Kinase MET in Canine Malignant Melanoma

  2023cites this paper
• The Application of pyrrolo[2, 3-d]pyrimidine scaffold in medicinal chemistry from 2017 to 2021.

  2023cites this paper
• Blocking the HGF-MET Pathway Induces Resolution of Neutrophilic Inflammation by Promoting Neutrophil Apoptosis and Efferocytosis.

  2023cites this paper
• Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer

  2022cites this paper
• EIF3H Knockdown Inhibits Malignant Melanoma through Regulating Cell Proliferation, Apoptosis and Cell Cycle.

  2021cites this paper
• Bispecific c-Met/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma

  2021cites this paper
• Overcoming resistance to targeted therapy using MET inhibitors in solid cancers: evidence from preclinical and clinical studies

  2021cites this paper
• RTK Inhibitors in Melanoma: From Bench to Bedside

  2021cites this paper
• Resistance to Molecularly Targeted Therapies in Melanoma

  2021cites this paper
• Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidine derivatives containing 1,8-naphthyridine-4-one fragment.

  2021cites this paper
• Assessment of In Vitro Anti-melanoma Potential of Ephedranthus pisocarpus R.E.Fr.

  2020cites this paper
• Design, Synthesis and Biological Evaluation of Novel 4-phenoxypyridine Derivatives Containing Semicarbazones Moiety as Potential c-Met Kinase Inhibitors.

  2020cites this paper
• Novel Peptide CM 7 Targeted c-Met with Antitumor Activity

  2020cites this paper
• Curcumol inhibits the proliferation and metastasis of melanoma via the miR-152-3p/PI3K/AKT and ERK/NF-κB signaling pathways

  2020cites this paper
• Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer

  2020cites this paper
• Exogen and endogen events trigger complex interactions in melanoma microenvironment

  2020cites this paper
• The role of MET in melanoma and melanocytic lesions.

  2019cites this paper
• Melanoma-Derived Exosomes Induce PD-1 Overexpression and Tumor Progression via Mesenchymal Stem Cell Oncogenic Reprogramming

  2019cites this paper
• Recent Progress in the Development of Small Molecule c-Met Inhibitors.

  2019cites this paper
• High-Affinity Human Anti-c-Met IgG Conjugated to Oxaliplatin as Targeted Chemotherapy for Hepatocellular Carcinoma

  2019cites this paper
• Targeting the ERK Signaling Pathway in Melanoma

  2019cites this paper
• Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities

  2018cites this paper
• Identification of novel N1-(2-aryl-1, 3-thiazolidin-4-one)-N3-aryl ureas showing potent multi-tyrosine kinase inhibitory activities.

  2018cites this paper
• Recent advances in the discovery of small molecule c-Met Kinase inhibitors.

  2018cites this paper
• Immunotherapies: Exploiting the Immune System for Cancer Treatment

  2018influential citation
• Protein Kinases as Tumor Biomarkers and Therapeutic Targets.

  2017cites this paper
• Recent advances in melanoma research via "omics" platforms.

  2017cites this paper
• Clinicopathological and prognostic significance of c-Met overexpression in breast cancer.

  2017cites this paper
• Melanoma from Molecular Pathways to Clinical Treatment: An Up to Date Review

  2017cites this paper
• Clinicopathological and prognostic significance of c-Met overexpression in breast cancer

  2017cites this paper